Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 8/2016

01-08-2016 | Original Article

MicroRNA-134 modulates glioma cell U251 proliferation and invasion by targeting KRAS and suppressing the ERK pathway

Authors: Yuguang Zhao, Dong Pang, Cui Wang, Shijiang Zhong, Shuang Wang

Published in: Tumor Biology | Issue 8/2016

Login to get access

Abstract

Dysregulated microRNA-134 (miR-134) has been observed in glioma carcinogenesis, and studies suggested that the ERK pathway plays vital roles in glioma cell growth and proliferation. However, the fundamental relationship between miR-134 and the ERK pathway in glioma has not been fully explained. As a result, this study was aimed to explore the underlying functions of miR-134 in human glioma. Intentionally overexpressed or inhibited miR-134 expression resulted from the transfection of miR-134 mimics, or miR-134 inhibitor within glioma cell line U251 was detected using RT-PCR. Both cell counting kit-8 (CCK-8) assays and Transwell assays were carried out to clarify the proliferation and invasion of U251 cells transfected with miR-134 mimics or miR-134 inhibitors. Our findings showed that miR-134 was significantly downexpressed in glioma tissues, and low miR-134 expression was significantly related to high histopathological grades. However, upregulated miR-134 expression restrained the proliferation and invasion of U251 cells in vitro. Kirsten rat sarcoma viral oncogene (KRAS), a vital factor for the ERK pathway, was directly targeted by miR-134 through its binding with the 3′-UTR of KRAS in glioma. Furthermore, KRAS expression exhibited a positive correlation with the activity of the ERK pathway. Overexpression of KRAS without 3′-UTR partly offsets the suppressive effect of miR-134 on glioma progression. Our data also indicated that miR-134 negatively modulated glioma progression and upregulated miR-134 triggered aberrant activation of the ERK pathway by targeting KRAS. Therefore, miR-134 might be considered as a benign therapeutic target of glioma.
Literature
1.
Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 2009;100:2235–41.CrossRefPubMed
2.
Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the united states in 2006–2010. Neuro-Oncology. 2013;15 Suppl 2:ii1–56.CrossRefPubMedCentralPubMed
3.
Zhang C, Bao Z, Zhang W, Jiang T. Progress on molecular biomarkers and classification of malignant gliomas. Frontiers of medicine. 2013;7:150–6.CrossRefPubMed
4.
Li A, Walling J, Ahn S, Kotliarov Y, Su Q, Quezado M, et al. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res. 2009;69:2091–9.CrossRefPubMedCentralPubMed
5.
Low SY, Ho YK, Too HP, Yap CT, Ng WH. MicroRNA as potential modulators in chemoresistant high-grade gliomas. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2014;21:395–400.CrossRef
6.
Malerba S, Galeone C, Pelucchi C, Turati F, Hashibe M, La Vecchia C, et al. A meta-analysis of coffee and tea consumption and the risk of glioma in adults. Cancer causes & control : CCC. 2013;24:267–76.CrossRefPubMed
7.
Michaud DS, Gallo V, Schlehofer B, Tjonneland A, Olsen A, Overvad K, et al. Reproductive factors and exogenous hormone use in relation to risk of glioma and meningioma in a large European cohort study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010;19:2562–9.CrossRef
8.
9.
Wang Y, Jiang T. Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett. 2013;331:139–46.CrossRefPubMed
10.
Zalatimo O, Zoccoli CM, Patel A, Weston CL, Glantz M. Impact of genetic targets on primary brain tumor therapy: what’s ready for prime time? Adv Exp Med Biol. 2013;779:267–89.CrossRefPubMed
11.
12.
Chen Y, Gao DY, Huang L. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev. 2015;81:128–41.CrossRefPubMed
13.
Hassan T, Smith SG, Gaughan K, Oglesby IK, O’Neill S, McElvaney NG, et al. Isolation and identification of cell-specific microRNAs targeting a messenger RNA using a biotinylated anti-sense oligonucleotide capture affinity technique. Nucleic Acids Res. 2013;41:e71.CrossRefPubMedCentralPubMed
14.
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.CrossRefPubMed
15.
Hummel R, Maurer J, Haier J. MicroRNAs in brain tumors: a new diagnostic and therapeutic perspective? Mol Neurobiol. 2011;44:223–34.CrossRefPubMed
16.
Turner JD, Williamson R, Almefty KK, Nakaji P, Porter R, Tse V, et al. The many roles of microRNAs in brain tumor biology. Neurosurg Focus. 2010;28:E3.CrossRefPubMed
17.
Wang K, Wang X, Zou J, Zhang A, Wan Y, Pu P, et al. mir-92b controls glioma proliferation and invasion through regulating Wnt/beta-catenin signaling via Nemo-like kinase. Neuro-Oncology. 2013;15:578–88.CrossRefPubMedCentralPubMed
18.
Simon M, Hosking FJ, Marie Y, Gousias K, Boisselier B, Carpentier C, et al. Genetic risk profiles identify different molecular etiologies for glioma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010;16:5252–9.CrossRef
19.
Li X, Ling N, Bai Y, Dong W, Hui GZ, Liu D, et al. Mir-16-1 plays a role in reducing migration and invasion of glioma cells. Anat Rec. 2013;296:427–32.CrossRef
20.
Tang H, Liu X, Wang Z, She X, Zeng X, Deng M, et al. Interaction of hsa-mir-381 and glioma suppressor LRRC4 is involved in glioma growth. Brain Res. 2011;1390:21–32.CrossRefPubMed
21.
Gaughwin P, Ciesla M, Yang H, Lim B, Brundin P. Stage-specific modulation of cortical neuronal development by Mmu-mir-134. Cereb Cortex. 2011;21:1857–69.CrossRefPubMed
22.
Christensen M, Larsen LA, Kauppinen S, Schratt G. Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for mir-134 in dendritogenesis in vivo. Frontiers in neural circuits. 2010;3:16.PubMedCentralPubMed
23.
Li J, Wang Y, Luo J, Fu Z, Ying J, Yu Y, et al. Mir-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells. FEBS Lett. 2012;586:3761–5.CrossRefPubMed
24.
Tay YM, Tam WL, Ang YS, Gaughwin PM, Yang H, Wang W, et al. MicroRNA-134 modulates the differentiation of mouse embryonic stem cells, where it causes post-transcriptional attenuation of Nanog and LRH1. Stem Cells. 2008;26:17–29.CrossRefPubMed
25.
Lages E, Guttin A, El Atifi M, Ramus C, Ipas H, Dupre I, et al. MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. PLoS One. 2011;6:e20600.CrossRefPubMedCentralPubMed
26.
Niu CS, Yang Y, Cheng CD. Mir-134 regulates the proliferation and invasion of glioblastoma cells by reducing Nanog expression. Int J Oncol. 2013;42:1533–40.PubMedCentralPubMed
27.
Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A. 2012;109:3041–6.CrossRefPubMedCentralPubMed
28.
Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells. 2009;27:2383–92.CrossRefPubMedCentralPubMed
29.
Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nature reviews Clinical oncology. 2009;6:519–27.CrossRefPubMed
30.
Liang QC, Xiong H, Zhao ZW, Jia D, Li WX, Qin HZ, et al. Inhibition of transcription factor STAT5b suppresses proliferation, induces G1 cell cycle arrest and reduces tumor cell invasion in human glioblastoma multiforme cells. Cancer Lett. 2009;273:164–71.CrossRefPubMed
31.
Liu Y, Zhang M, Qian J, Bao M, Meng X, Zhang S, et al. Mir-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal transition by targeting KRAS in renal cell carcinoma cells. DNA Cell Biol. 2015;34:429–36.CrossRefPubMedCentralPubMed
32.
Kim M, Slack FJ. MicroRNA-mediated regulation of KRAS in cancer. Journal of hematology & oncology. 2014;7:84.CrossRef
33.
Zhang Y, Kim J, Mueller AC, Dey B, Yang Y, Lee DH, et al. Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5b, and glioblastoma. Cell Death Differ. 2014;21:720–34.CrossRefPubMedCentralPubMed
34.
Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, et al. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res. 2010;70:6804–14.CrossRefPubMedCentralPubMed
35.
Miller KA, Yeager N, Baker K, Liao XH, Refetoff S, Di Cristofano A. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res. 2009;69:3689–94.CrossRefPubMedCentralPubMed
36.
Dontula R, Dinasarapu A, Chetty C, Pannuru P, Herbert E, Ozer H, et al. MicroRNA 203 modulates glioma cell migration via Robo1/ERK/MMP-9 signaling. Genes & cancer. 2013;4:285–96.CrossRef
37.
Han S, Li Z, Master LM, Master ZW, Wu A. Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin beta1-ERK pathway. Br J Cancer. 2014;111:1400–9.CrossRefPubMedCentralPubMed
38.
Komori T. Pathology and genetics of diffuse gliomas in adults. Neurol Med Chir. 2015;55 Suppl 1:28–37.CrossRef
39.
Hsu SM, Soban E. Color modification of diaminobenzidine (dab) precipitation by metallic ions and its application for double immunohistochemistry. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. 1982;30:1079–82.CrossRef
40.
41.
Zhong J, Li B. Reduced expression of microRNA-134 correlates with malignancy and poor prognosis in human glioma. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2015;22:583–7.CrossRef
42.
Yin C, Wang PQ, Xu WP, Yang Y, Zhang Q, Ning BF, et al. Hepatocyte nuclear factor-4alpha reverses malignancy of hepatocellular carcinoma through regulating mir-134 in the DLK1-DIO3 region. Hepatology. 2013;58:1964–76.CrossRefPubMed
43.
Zha R, Guo W, Zhang Z, Qiu Z, Wang Q, Ding J, et al. Genome-wide screening identified that mir-134 acts as a metastasis suppressor by targeting integrin beta1 in hepatocellular carcinoma. PLoS One. 2014;9:e87665.CrossRefPubMedCentralPubMed
44.
Shin YM, Yun J, Lee OJ, Han HS, Lim SN, An JY, et al. Diagnostic value of circulating extracellular mir-134, mir-185, and mir-22 levels in lung adenocarcinoma-associated malignant pleural effusion. Cancer research and treatment : official journal of Korean Cancer Association. 2014;46:178–85.CrossRef
45.
Liu CJ, Shen WG, Peng SY, Cheng HW, Kao SY, Lin SC, et al. Mir-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene. International journal of cancer Journal international du cancer. 2014;134:811–21.CrossRefPubMed
46.
47.
Ryu MJ, Liu Y, Zhong X, Du J, Peterson N, Kong G, et al. Oncogenic Kras expression in postmitotic neurons leads to s100a8-s100a9 protein overexpression and gliosis. J Biol Chem. 2012;287:22948–58.CrossRefPubMedCentralPubMed
48.
Milinkovic VP, Skender Gazibara MK, Manojlovic Gacic EM, Gazibara TM, Tanic NT. The impact of TP53 and RAS mutations on cerebellar glioblastomas. Exp Mol Pathol. 2014;97:202–7.CrossRefPubMed
49.
Zheng L, Zhang Y, Liu Y, Zhou M, Lu Y, Yuan L, et al. Mir-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer. J Transl Med. 2015;13:252.CrossRefPubMedCentralPubMed
50.
Ritchie W, Rasko JE, Flamant S. MicroRNA target prediction and validation. Adv Exp Med Biol. 2013;774:39–53.CrossRefPubMed
51.
Chen T, Gao F, Feng S, Yang T, Chen M. MicroRNA-134 regulates lung cancer cell H69 growth and apoptosis by targeting WWOX gene and suppressing the ERK1/2 signaling pathway. Biochem Biophys Res Commun. 2015;464:748–54.CrossRefPubMed
52.
Wang XM, Jia RH, Wei D, Cui WY, Jiang W. Mir-134 blockade prevents status epilepticus like-activity and is neuroprotective in cultured hippocampal neurons. Neurosci Lett. 2014;572:20–5.CrossRefPubMed
53.
Kitamura K, Seike M, Okano T, Matsuda K, Miyanaga A, Mizutani H, et al. Mir-134/487b/655 cluster regulates TGF-beta-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther. 2014;13:444–53.CrossRefPubMed
54.
Zhang X, Wang H, Zhang S, Song J, Zhang Y, Wei X, et al. Mir-134 functions as a regulator of cell proliferation, apoptosis, and migration involving lung septation. In vitro cellular & developmental biology Animal. 2012;48:131–6.CrossRef
55.
Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7:295–308.CrossRefPubMed
56.
Bodemann BO, White MA. Ral GTPases and cancer: linchpin support of the tumorigenic platform. Nat Rev Cancer. 2008;8:133–40.CrossRefPubMed
Metadata
Title
MicroRNA-134 modulates glioma cell U251 proliferation and invasion by targeting KRAS and suppressing the ERK pathway
Authors
Yuguang Zhao
Dong Pang
Cui Wang
Shijiang Zhong
Shuang Wang
Publication date
01-08-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 8/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5027-9

Other articles of this Issue 8/2016

Tumor Biology 8/2016 Go to the issue

Original Article

Regulation of proliferation, angiogenesis and apoptosis in hepatocellular carcinoma by miR-26b-5p

Original Article

Pre-diagnostic serum levels of EGFR and ErbB2 and genetic glioma risk variants: a nested case-control study

Original Article

Overexpression of MicroRNA-221 is associated with poor prognosis in non-small cell lung cancer patients

Original Article

Clinical impact of circulating microRNAs as blood-based marker in childhood acute lymphoblastic leukemia

Original Article

MIIP expression predicts outcomes of surgically resected esophageal squamous cell carcinomas

Original Article

Toll-like receptor 5 and 7 expression in adenoid cystic carcinoma of major salivary glands
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits